Ashim Mitra

Dr. Ashim Mitra


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
RGRipal Gaudana
Ripal Gaudana
HAHari Krishna Ananthula
Hari Krishna Ananthula
APAshwin Parenky
Ashwin Parenky
AMAshim Mitra
Ashim Mitra

1 January 2013 in World Journal of Pharmacology
Verified
Journal Article
Open access
APAshaben Patel
Ashaben Patel
KCKishore Cholkar
Kishore Cholkar
VAVibhuti Agrahari
Vibhuti Agrahari
AMAshim Mitra
Ashim Mitra
Ocular drug delivery systems: An overview

1 April 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JRJwala Renukuntla
Jwala Renukuntla
AVAswani Dutt Vadlapudi
Aswani Dutt Vadlapudi
APAshaben Patel
Ashaben Patel
SBSai HS. Boddu
Sai HS. Boddu
AMAshim Mitra
Ashim Mitra

29 August 2008 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
RGRipal Gaudana
Ripal Gaudana
JJJ. Jwala
J. Jwala
SBSai HS. Boddu
Sai HS. Boddu
AMAshim Mitra
Ashim Mitra
Anatomy and physiology of the eye makes it a highly protected organ. Designing an effective therapy for ocular diseases, especially for the posterior segment, has been considered as a formidable task. Limitations of topical and intravitreal route of administration have challenged scientists to find alternative mode of administration like periocular routes. Transporter targeted drug delivery has generated a great deal of interest in the field because of its potential to overcome many barriers associated with current therapy. Application of nanotechnology has been very promising in the treatment of a gamut of diseases. In this review, we have briefly discussed several ocular drug delivery systems such as microemulsions, nanosuspensions, nanoparticles, liposomes, niosomes, dendrimers, implants, and hydrogels. Potential for ocular gene therapy has also been described in this article. In near future, a great deal of attention will be paid to develop non-invasive sustained drug release for both anterior and posterior segment eye disorders. A better understanding of nature of ocular diseases, barriers and factors affecting in vivo performance, would greatly drive the development of new delivery systems. Current momentum in the invention of new drug delivery systems hold a promise towards much improved therapies for the treatment of vision threatening disorders.

1 February 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
AMAbhirup Mandal
Abhirup Mandal
RBRohit Bisht
Rohit Bisht
Ilva RupenthalIlva Rupenthal
Ilva Rupenthal
AMAshim Mitra
Ashim Mitra

31 October 2016 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
VAVibhuti Agrahari
Vibhuti Agrahari
AMAbhirup Mandal
Abhirup Mandal
VAVivek Agrahari
Vivek Agrahari
HTHoang M. Trinh
Hoang M. Trinh
MJMary Joseph
Mary Joseph
AMAshim Mitra
Ashim Mitra